The first bellwether trials for those cases are slated for next February. Meanwhile, almost 1,000 cases in the Philadelphia mass tort are scheduled for next August. All of these cases claim that the Xarelto manufacturers, Janssen Pharmaceuticals, and distributors -- sold in the US by Johnson & Johnson and overseas by Bayer-- knowingly put patients at risk for uncontrollable bleeds.
READ MORE XARELTO LEGAL NEWS
As well, an investigation regarding use of a defective medical device that was used in Xarelto clinical trials may have resulted in false data during the clinical trials by showing Xarelto to be more effective than it really was. This data was also sent to reputable medical journals, according to the New York Times (May 2016).Lawyers for Xarelto plaintiffs claim that the esteemed New England Journal of Medicine left out critical data in the drug’s analysis.
According to the Times Xarelto had nearly $2 billion in United States sales last year and is the best seller in a new category of drugs seeking to replace warfarin, an older blood thinner.